Capsida Biotherapeutics to present preliminary findings on engineered AAV capsids at ASGCT annual meeting

The gene therapy platform company Capsida Biotherapeutics (Thousand Oaks, California) is gearing up to unveil initial data on its engineered adeno-associated virus (AAV) capsids at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16–20 in Los Angeles.

In developing these capsids, Capsida Chief Scientific Officer Susan Catalano explained that the company employed directed evolution and a high-throughput screening platform to optimize capsid performance across key domains. “We start with a disease and aim to create the best possible therapy, as opposed to trying to mold a disease profile around the limitations of wildtype capsids,” Catalano said.

Preliminary results suggest these engineered AAV capsids can reach up to 68% of neurons across multiple brain regions when delivered intravenously. That finding could translate to new possibilities in gene therapies targeting common neurological diseases that have…

Read more
  • 0